183 related articles for article (PubMed ID: 27283923)
1. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.
Howard CB; Fletcher N; Houston ZH; Fuchs AV; Boase NR; Simpson JD; Raftery LJ; Ruder T; Jones ML; de Bakker CJ; Mahler SM; Thurecht KJ
Adv Healthc Mater; 2016 Aug; 5(16):2055-68. PubMed ID: 27283923
[TBL] [Abstract][Full Text] [Related]
2. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
3. One-step mixing with humanized anti-mPEG bispecific antibody enhances tumor accumulation and therapeutic efficacy of mPEGylated nanoparticles.
Kao CH; Wang JY; Chuang KH; Chuang CH; Cheng TC; Hsieh YC; Tseng YL; Chen BM; Roffler SR; Cheng TL
Biomaterials; 2014 Dec; 35(37):9930-9940. PubMed ID: 25212525
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
5. Active Tumoral/Tumor Environmental Dual-Targeting by Non-Covalently Arming with Trispecific Antibodies or Dual-Bispecific Antibodies on Docetaxel-Loaded mPEGylated Nanocarriers to Enhance Chemotherapeutic Efficacy and Minimize Systemic Toxicity.
Cheng WJ; Lin SY; Chen M; Chen LC; Ho HO; Chuang KH; Sheu MT
Int J Nanomedicine; 2021; 16():4017-4030. PubMed ID: 34140769
[TBL] [Abstract][Full Text] [Related]
6. Modulating Targeting of Poly(ethylene glycol) Particles to Tumor Cells Using Bispecific Antibodies.
Cui J; Ju Y; Houston ZH; Glass JJ; Fletcher NL; Alcantara S; Dai Q; Howard CB; Mahler SM; Wheatley AK; De Rose R; Brannon PT; Paterson BM; Donnelly PS; Thurecht KJ; Caruso F; Kent SJ
Adv Healthc Mater; 2019 May; 8(9):e1801607. PubMed ID: 30868751
[TBL] [Abstract][Full Text] [Related]
7. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
[TBL] [Abstract][Full Text] [Related]
8. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics.
Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ
Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092
[TBL] [Abstract][Full Text] [Related]
9. Cellular Targeting of Bispecific Antibody-Functionalized Poly(ethylene glycol) Capsules: Do Shape and Size Matter?
Song D; Cui J; Ju Y; Faria M; Sun H; Howard CB; Thurecht KJ; Caruso F
ACS Appl Mater Interfaces; 2019 Aug; 11(32):28720-28731. PubMed ID: 31369234
[TBL] [Abstract][Full Text] [Related]
10. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
[TBL] [Abstract][Full Text] [Related]
11. Humanized bispecific antibody (mPEG × HER2) rapidly confers PEGylated nanoparticles tumor specificity for multimodality imaging in breast cancer.
Cheng YA; Wu TH; Wang YM; Cheng TL; Chen IJ; Lu YC; Chuang KH; Wang CK; Chen CY; Lin RA; Chen HJ; Liao TY; Liu ES; Chen FM
J Nanobiotechnology; 2020 Aug; 18(1):118. PubMed ID: 32854720
[TBL] [Abstract][Full Text] [Related]
12. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
13. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
[TBL] [Abstract][Full Text] [Related]
14. Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X; Wu QP; Ke S; Ellis L; Charnsangavej C; Delpassand AS; Wallace S; Li C
J Nucl Med; 2001 Oct; 42(10):1530-7. PubMed ID: 11585869
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of tumor tropism of mPEGylated nanoparticles by anti-mPEG bispecific antibody for ovarian cancer therapy.
Lin WW; Cheng YA; Li CC; Ho KW; Chen HJ; Chen IU; Huang BC; Liu HJ; Lu YC; Cheng CM; Huang MY; Lai HW; Cheng TL
Sci Rep; 2021 Apr; 11(1):7598. PubMed ID: 33828191
[TBL] [Abstract][Full Text] [Related]
16. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
[TBL] [Abstract][Full Text] [Related]
17. Designed multifunctional polymeric nanomedicines: long-term biodistribution and tumour accumulation of aptamer-targeted nanomaterials.
Fletcher NL; Houston ZH; Simpson JD; Veedu RN; Thurecht KJ
Chem Commun (Camb); 2018 Oct; 54(82):11538-11541. PubMed ID: 30182121
[TBL] [Abstract][Full Text] [Related]
18. Enhanced drug internalization and therapeutic efficacy of PEGylated nanoparticles by one-step formulation with anti-mPEG bispecific antibody in intrinsic drug-resistant breast cancer.
Cheng YA; Chen IJ; Su YC; Cheng KW; Lu YC; Lin WW; Hsieh YC; Kao CH; Chen FM; Roffler SR; Cheng TL
Biomater Sci; 2019 Aug; 7(8):3404-3417. PubMed ID: 31251311
[TBL] [Abstract][Full Text] [Related]
19. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
20. Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.
Mehrabadi FS; Adelmann J; Gupta S; Wedepohl S; Calderón M; Brinkmann U; Haag R
Curr Cancer Drug Targets; 2016; 16(7):639-49. PubMed ID: 26853135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
